Adicet Bio Inc. Common Stock (ACET)
Stock · NASDAQ · Health Care
$4.58as of 10/16/2026
Price chart
Active signals
ACET Signal Track Record
How signals performed across all stocks →What ACET's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | -4.9% | 40% | September 15, 2026 |
| Bollinger Band Breakdown | 20 | -0.8% | 45% | September 15, 2026 |
| Bollinger Band Breakout | 19 | +1.9% | 53% | May 29, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +10.6% | 80% | August 12, 2026 |
| Any 20-session window (baseline) | -4.5% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACET
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edite…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 102
- Website
- www.adicetbio.com/
Fundamentals
- 1-day range
- $4.57$5.14
- Market cap
- $74.13M
- P/E (trailing)
- —
- P/E (forward)
- -1.13
- EPS (trailing)
- $-13.02
- Dividend yield
- —
- Beta
- 1.67
- Avg. volume
- 184.7K
- Dividend pay date
- September 16, 2020
Forecasts
6 analyst ratings
Adicet Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACETAdicet Bio Inc. Common Stock$4.57▼ 11.09%Market cap $74.13MP/E —$4.8$17.04
- TLPHTalphera Inc. Common Stock$1.08▲ 0.93%Market cap $74.22MP/E —$0.6866$1.57
- OSTXOS Therapies Incorporated Common Stock$1.32▼ 6.38%Market cap $74.23MP/E —$1.15$2.25
- SPROSpero Therapeutics Inc. Common Stock$1.1▼ 2.65%Market cap $73.53MP/E 8.91$1.08$3.08
- NMADNomad Power Solutions Inc. Common Stock$3.88▼ 5.13%Market cap $75.50MP/E —$3.12$7.7
- GANXGain Therapeutics Inc. Common Stock$1.26▼ 5.26%Market cap $75.92MP/E —$1.3$4.34
- ACRVAcrivon Therapeutics Inc. Common Stock$1.64▼ 6.82%Market cap $72.33MP/E —$1.27$3.56
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACET Adicet Bio Inc. Common Stock | $74.13M | — | $4.57 | ▼ 11.09% | $4.8$17.04 |
| TLPH Talphera Inc. Common Stock | $74.22M | — | $1.08 | ▲ 0.93% | $0.6866$1.57 |
| OSTX OS Therapies Incorporated Common Stock | $74.23M | — | $1.32 | ▼ 6.38% | $1.15$2.25 |
| SPRO Spero Therapeutics Inc. Common Stock | $73.53M | 8.91 | $1.1 | ▼ 2.65% | $1.08$3.08 |
| NMAD Nomad Power Solutions Inc. Common Stock | $75.50M | — | $3.88 | ▼ 5.13% | $3.12$7.7 |
| GANX Gain Therapeutics Inc. Common Stock | $75.92M | — | $1.26 | ▼ 5.26% | $1.3$4.34 |
| ACRV Acrivon Therapeutics Inc. Common Stock | $72.33M | — | $1.64 | ▼ 6.82% | $1.27$3.56 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Adicet Bio’s Prula-Cel Delivers 54% Lupus Remission Rate at 12 MonthsYahoo · 10/3/2026
- Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis - SlideshowSeekingAlpha · 9/30/2026
- Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28Benzinga · 9/29/2026
- Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans AdvanceYahoo · 9/28/2026
- Let's uncover which stocks are experiencing notable gaps during today's session.ChartMill · 9/28/2026
- Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus Nephritis TranscriptSeekingAlpha · 9/28/2026
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga · 9/28/2026
- Is Tenet Healthcare (THC) Outperforming Other Medical Stocks This Year?Yahoo · 9/28/2026
Insider Activity
Insider Actions →- Lloyd Klickstein · August 5, 2026 · Grant18.3K
- Katie Peng · June 21, 2026 · Grant4.2K
- Lloyd Klickstein · June 21, 2026 · Grant4.2K
- Andrew Sinclair · June 21, 2026 · Grant4.2K
- Michael Grissinger · June 21, 2026 · Grant4.2K
- Jeffrey Chodakewitz · June 21, 2026 · Grant4.2K
- Steve Dubin · June 21, 2026 · Grant4.2K
- Blake Aftab · June 19, 2026 · Grant55.0K
- Chen Schor · June 19, 2026 · Grant55.0K
- RA Capital Healthcare Fund LP · April 27, 2026 · J250.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 6.34M
- Total value held
- $42.38M
- Institutional holders
- 45
- Unknown1.18M
- Unknown1.03M
- Unknown626.6K
- Unknown381.8K
- Unknown336.5K
- Unknown313.1K
- Unknown274.4K
- Unknown250.2K
- Unknown232.6K
- Unknown222.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.